前立腺癌に対するEstramutine Phosphate(Estracyt)の効果

概要

論文の詳細を見る
Estramustine phosphate (Estracyt) was administered per os to 23 patients with carcinoma of the prostate and its therapeutic effect was investigated. The following results were obtained. 1. Group I consisting of 13 cases without previous treatment showed good response in all. 2. Group II consisting of 10 cases resistant to the hormone therapy showed response in 30% of them. 3. There was an obvious difference between Group I and II in the improvement of general condition, subjective symptoms, amount of residual urine, anemia, acid and alkaline phosphatase level, local findings, metastatic lesions and urethrographic findings. For example, urethrographic improvement was obtained in 83.3% of Group I cases and 25.0% of Group II cases. 4. Of side effects, the most frequently seen was that of the breast. Others were also related with the estrogenic effect. The side effects upon the liver and hemic system must be considered. 5. Estracyt is a useful drug for carcinoma of the prostate not only in previously untreated cases but in hormone-resistant cases. It is, however, uneffective for the advanced cases. Choice of the cases is therefore important.
泌尿器科紀要刊行会の論文